Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma

This is a multi-center, multinational phase 2 trial that aims to explore the use of molecular and clinical risk-directed therapy in treatment of children 0-4.99 years of age with newly diagnosed medulloblastoma.

Trial Details

NCT ID
NCT05535166
Phase
PHASE2
Sponsor
St. Jude Children's Research Hospital
Status
RECRUITING
Cancer Type
Brain Cancer
Interventions
  • Surgical resection
  • Ommaya/VPS
  • Methotrexate
  • Cisplatin
  • Vincristine
  • Cyclophosphamide
Locations (sample)
  • Palo Alto, California, United States|37.44188,-122.14302
  • Orlando, Florida, United States|28.53834,-81.37924
  • Tampa, Florida, United States|27.94752,-82.45843
  • Ann Arbor, Michigan, United States|42.27756,-83.74088
  • Minneapolis, Minnesota, United States|44.97997,-93.26384

Key Eligibility Criteria

  • Participants with presumptive/suspected newly diagnosed medulloblastoma.
  • Participant meets one of the following criteria at the time of screening:
  • Age \< 36 months OR Age ≥ 36 months and \< 60 months with presumptive/suspected non-metastatic disease
  • Participant must have adequate tumor tissue from primary tumor for central review of pathology and molecular classification by methylation and IHC

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Brain Cancer Trials on Trialify →